United Republic of Tanzania

Population 2018  56 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>142 (67–245)</td>
<td>253 (119–435)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>40 (19–69)</td>
<td>71 (34–122)</td>
</tr>
<tr>
<td>MDR/RR-TB incidenceº</td>
<td>1.9 (0.67–3.7)</td>
<td>3.3 (1.2–6.6)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>22 (10–40)</td>
<td>40 (18–70)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>16 (7.8–27)</td>
<td>29 (14–49)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

** New cases  0.97% (0.4–1.6)
Previously treated cases  13% (11–15)

TB case notifications, 2018

Total new and relapse  74 692
- % tested with rapid diagnostics at time of diagnosis  18%
- % with known HIV status  99%
- % pulmonary  79%
- % bacteriologically confirmedºº  48%
- % children aged 0–14 years  14%
- % women  33%
- % men  53%
Total cases notified  75 828

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018  53% (30–110)
TB patients facing catastrophic total costs
TB case fatality ratio (estimated mortality/estimated incidence), 2018  30% (11–53)
TB/HIV care in new and relapse TB patients, 2018
Patients with known HIV status who are HIV-positive  20 695  28%
- on antiretroviral therapy  20 337  98%

Drug-resistant TB care, 2018
% of bacteriologically confirmed TB cases tested for rifampicin resistanceººº
- New cases  70%
- Previously treated cases  81%
Laboratory-confirmed cases*
MDR/RR-TB: 449, XDR-TB: 0
Patients started on treatment**
MDR/RR-TB: 409, XDR-TB: 0
MDR/RR-TB cases tested for resistance to second-line drugs  62

Treatment success rate and cohort size

New and relapse cases registered in 2017  90%  68 278
Previously treated cases, excluding relapse, registered in 2017  84%  1 250
HIV-positive TB cases registered in 2017  80%  21 349
MDR/RR-TB cases started on second-line treatment in 2016  80%  158
XDR-TB cases started on second-line treatment in 2016  0

TB preventive treatment, 2018
% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment  22% (20–24)

TB financing, 2019

National TB budget (US$ millions)  62
Funding source: 4% domestic, 24% international, 72% unfunded

* Ranges represent uncertainty intervals
º MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
ºº MDR-TB: multidrug-resistant tuberculosis; XDR-TB: extensively drug-resistant tuberculosis
ººº Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-04-07